Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adapt Out COVID
PACTR202111591363732Phase 3Not yet recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in coronavirus disease 2019 (COVID-19) comparing casirivimab + imdevimab, SAB-185 and placebo/control (3 arms). Primary endpoints: Clinical symptom duration, Virologic response and 2 more. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
casirivimab + imdevimabSAB-185
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on PACTR202111591363732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202111591363732.